SIRPA and neoplasm: The CD47–SIRP interaction promotes the inhibition of myosin-IIA build-up at the level of the phagocytic synapse, as well as the recruiting of downstream Src homology-2 domain-containing protein tyrosine phosphatases (SHP-1 and SHP-2), thus preventing macrophage-mediated tumor phagocytosis [56].